Regeneron leaps into the blockbuster race to develop off-the-shelf immune cell cancer therapies
A year ago, Sanofi agreed to pay Regeneron $1.8 billion-plus to partner on its anti-PD1 checkpoint program. Today, biotech heavyweight Regeneron is jumping into CAR-Ts and TCR tech, determined to leap directly into a blockbuster brawl with a plan to emerge as a leader in the fast-growing immuno-oncology field. And it’s made the latest in a handful of rare biotech deals to partner on the technology it needs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
